Planned
IPAX3 (131I-TLX-203)
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)
- Principal investigator : Prof. dr. Paul Clement
- Sponsor: Telix Pharma
- More information : NCT07100730
- Indication: Glioblastoma
- Internal reference number : s71171
MIRAGE-HN
A Phase II trial evaluating treatment intensification with ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor: Clinique universitaire Saint Luc
- More information :
- Indication:
- Internal reference number : s71428
OptimUM-11 - IDEA196-011
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF ADJUVANT DAROVASERTIB AND CRIZOTINIB IN PARTICIPANTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA
- Principal investigator : Prof. dr. Paul Clement
- Sponsor: IDEAYA
- More information :
- Indication:
- Internal reference number : s72531
Ongoing
Origami 5 (61186372HNC3001)
A Phase 3 Open-Label Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, In Comparison with Standard of Care Platinum/Pembrolizumab/5-FU, in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor: Johnson&Johnson
- More information : NCT07276399
- Indication:
- Internal reference number : s71117
VIGOR (EORTC 2427 BTG)
Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor: EORTC
- More information : NCT06809322
- Indication:
- Internal reference number : s70681